Wire flash
HealthUpcoming FDA Peptide Meeting Sparks Industry Debate
Editorial responsibility
- No named human review is recorded for this page.
- Source reporting is collected, normalized, translated or condensed automatically when needed.
- Automatically published source-backed update
Health and Human Services Secretary Robert F. Kennedy Jr.'s newly reformed Pharmacy Compounding Advisory Committee is set to meet this week to consider adding more peptides to the list of substances that compounding pharmacies can legally produce. The meeting has put the pharmaceutical industry on edge, as observers are divided over whether peptides—which Kennedy has publicly stated he is a 'big fan of'—should be regulated as pharmaceuticals. The debate centers on balancing patient access to compounded peptides with safety and efficacy concerns typically associated with FDA-approved drugs. The outcome could significantly impact the compounding pharmacy sector and the broader peptide market.
Source report
Washington — Health and Human Services (HHS) Secretary Robert F. Kennedy Jr.'s recently reformed committee on compounding pharmacies is scheduled to meet this week to consider adding more peptides to the list of substances that pharmacies are permitted to produce.
The meeting has sparked debate among industry observers, who remain divided over whether peptides—substances Kennedy has described himself as a "big fan of"—should be treated as pharmaceuticals.
The Pharmacy Compounding Advisory Committee will deliberate on the proposed expansion.
Source
Just In NewsWestern
Part of this Story
Upcoming FDA Peptide Meeting Sparks Industry Debate